Lim JU, et al. - Researchers investigated how overall survival in driver mutation-negative non-small cell lung cancer (NSCLC) patients undergoing conventional chemotherapy as the first-line treatment is influenced by COPD. They reviewed medical records from January 2008 to December 2015 from six university hospitals for 197 patients, of whom 92 (46.7%) were COPD patients and 105 (53.3%) were non-COPD patients, with stage IIIB and IV NSCLC. Findings demonstrated a negative influence of COPD on overall survival in stage IV NSCLC and smoker NSCLC patients who underwent conventional chemotherapy.